rVSV∆G-MARV-GP Vaccine for Marburg Virus Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose-escalation Treatment
Participants receive one of four escalating doses of the rVSV∆G-MARV-GP vaccine or placebo, with safety assessments conducted after each dose level
Safety Assessment
Safety and tolerability of the vaccine are assessed, including unsolicited and solicited reactogenicity and adverse events
Follow-up
Participants are monitored for safety and immunogenicity, including antibody responses, up to 6 months after immunization
What Are the Treatments Tested in This Trial?
Interventions
- rVSV∆G-MARV-GP
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
International AIDS Vaccine Initiative
Lead Sponsor
Biomedical Advanced Research and Development Authority
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.